Chronic hypertension:first-trimester blood pressure control and likelihood of severe hypertension, preeclampsia and small for gestational age by Nzelu, Diane et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ajog.2017.12.235
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Nzelu, D., Dumitrascu-Biris, D., Nicolaides, K. H., & kametas, N. A. (2018). Chronic hypertension: first-trimester
blood pressure control and likelihood of severe hypertension, preeclampsia and small for gestational age.
American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2017.12.235
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
Chronic hypertension: first-trimester blood pressure control and likelihood of severe
hypertension, preeclampsia and small for gestational age
Diane Nzelu, M.D., Dan Dumitrascu-Biris, M.D., Kypros H. Nicolaides, M.D., Nikos A.
kametas, M.D.
PII: S0002-9378(17)32809-0
DOI: 10.1016/j.ajog.2017.12.235
Reference: YMOB 12023
To appear in: American Journal of Obstetrics and Gynecology
Received Date: 27 October 2017
Revised Date: 9 December 2017
Accepted Date: 21 December 2017
Please cite this article as: Nzelu D, Dumitrascu-Biris D, Nicolaides KH, kametas NA, Chronic
hypertension: first-trimester blood pressure control and likelihood of severe hypertension, preeclampsia
and small for gestational age, American Journal of Obstetrics and Gynecology (2018), doi: 10.1016/
j.ajog.2017.12.235.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Chronic hypertension: first-trimester blood pressure control and likelihood of 
severe hypertension, preeclampsia and small for gestational age 
 
 
Diane NZELU, M.D., Dan DUMITRASCU-BIRIS, M.D., Kypros H. NICOLAIDES, M.D., 
Nikos A. KAMETAS, M.D. 
 
King's College Hospital, London, UK. 
 
Conflict of interest statement: The authors report no conflict of interest. 
 
Sources of funding: No funding was received for this study.  
 
 
Corresponding author: 
Nikos Kametas  
Antenatal Hypertension Clinic, 
Fetal Medicine Research Institute, 
King's College Hospital, 
16-20 Windsor Walk,  
Denmark Hill, London SE5 8BB 
Telephone: + 44 20 3299 2465  
e-mail: nick.kametas@kcl.ac.uk  
 
Abstract word count: 439 
Text word count: 2537 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Condensation 
The pregnancy outcome of chronic hypertension is influenced by the need and 
response to anti-hypertensive agents at the time of the first prenatal visit. 
 
Short version of article title 
Stratification of chronic hypertension in pregnancy. 
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ABSTRACT 
 
Background: There is extensive evidence that pre-pregnancy chronic hypertension is 
associated with high risk of development of severe hypertension and preeclampsia and 
birth of small for gestational age neonates. However, previous studies have not reported 
whether anti-hypertensive use, blood pressure control or normalization of blood 
pressure during early pregnancy influence the rates of these pregnancy complications. 
 
Objective: To stratify women with pre-pregnancy chronic hypertension according to the 
use of antihypertensive medications and level of blood pressure control at the first 
hospital visit during the first-trimester of pregnancy and examine the rates of severe 
hypertension, preeclampsia and birth of small for gestational age neonates according to 
such stratification.   
 
Study Design: Prospective study of 586 women with pre-pregnancy chronic 
hypertension, in the absence of renal or liver disease, booked at a dedicated clinic for 
the management of hypertension in pregnancy. The patients had singleton pregnancies 
and were subdivided according to findings in their first visit into group 1 (n=199), with 
blood pressure <140/90 mmHg without antihypertensive medication, group 2 (n=220), 
with blood pressure <140/90 mmHg with antihypertensive medication and group 3 
(n=167), with systolic blood pressure >140 mmHg and or diastolic blood pressure >90 
mmHg despite antihypertensive medication. In the subsequent management of these 
pregnancies our policy was to maintain the blood pressure at 130-140 / 80-90 mmHg 
with use of antihypertensive medication; antihypertensive drugs were stopped if the 
blood pressure was persistently less than 130/80 mmHg. The outcome measures were 
severe hypertension (systolic blood pressure >160 mmHg and / or diastolic blood 
pressure >110 mmHg), preterm and term preeclampsia (in addition to hypertension at 
least one of renal involvement, liver impairment, neurological complications or 
thrombocytopenia), and birth of small for gestational age neonates (birth weight <5th 
percentile for gestational age). The incidence of these complications was compared in 
the three strata.   
 
Results: The median gestational age at presentation was 10.0 (interquartile range 9.1-
11.0) weeks. In groups 2 and 3, compared to group 1, there was a significantly higher 
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body mass index, incidence of black racial origin and history of preeclampsia in a 
previous pregnancy. There was a significant increase from group 1 to group 3 in 
incidence of severe hypertension (10.6%, 22.2% and 52.1%), preterm preeclampsia 
with onset at <37 weeks of gestation (7.0%, 15.9% and 20.4%), and small for 
gestational age (13.1%, 17.7% and 21.1%), but not term preeclampsia with onset at 
>37 weeks of gestation (9.5%, 9.1% and 6.6%). 
 
Conclusions: In women with pre-pregnancy chronic hypertension, the rates of 
development of severe hypertension, preterm preeclampsia and small for gestational 
age are related to use of antihypertensive medications and level of blood pressure 
control at the first hospital visit during the first-trimester of pregnancy. 
 
 
 
 
Key words: Chronic hypertension, Pregnancy, Preeclampsia, Small for gestational age; 
Severe hypertension; Antihypertensive drugs; Pregnancy outcome.  
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Introduction  
 
Chronic hypertension is found in 1-5% of pregnancies and the frequency increases with 
age and weight and is higher in Black than in White individuals.1 In most cases the 
condition precedes the onset of pregnancy (pre-pregnancy) and in others the 
hypertension develops in the first 20 weeks of pregnancy.2, 3 In chronic hypertension 
there is a high risk for development of severe hypertension or preeclampsia (PE) and 
delivery of small for gestational age (SGA) neonates.1, 4-9 Pregnancy is associated with 
substantial decrease in peripheral resistance, from as early as 5 weeks of gestation, 
and many women with pre-pregnancy chronic hypertension will therefore have 
normalization in their blood pressure (BP) even without the need for antihypertensive 
medications.10 Consequently, women with pre-pregnancy chronic hypertension fall into 
three broad categories in relation to their BP control when they present to hospital in the 
first trimester of pregnancy: those with BP <140/90 mmHg without antihypertensive 
medication (group 1), those with BP <140/90 mmHg with antihypertensive medication 
(group 2) and those with persistent hypertension (systolic BP >140 mmHg and or 
diastolic BP >90 mmHg) despite antihypertensive medication (group 3). However, 
previous studies reporting on the association between chronic hypertension and 
development of severe hypertension or PE and birth of SGA neonates have not 
distinguished between these three groups of women and have not reported whether 
anti-hypertensive use, BP control or normalization of BP during early pregnancy 
influence the rates of pregnancy complications.1-7 Furthermore, many of the previous 
studies include women with secondary hypertension, such as those with renal disease, 
thereby introducing bias since renal disease is a significant risk factor for the 
development of PE independent of chronic hypertension.11, 12 
 
The objective of this study is to stratify women with pre-pregnancy chronic hypertension 
according to the use of antihypertensive medications and level of BP control at the first 
hospital visit during the first-trimester of pregnancy and examine the frequency of 
severe hypertension, PE and SGA according to such stratification.   
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Methods 
 
Study population  
 
This was an analysis of prospectively collected data in the Antenatal Hypertension 
Clinic at King’s College Hospital, London between January 2011 and January 2016. 
According to local protocols, pregnant women with pre-pregnancy hypertension are 
referred to this clinic from the first trimester for the management of their pregnancy. The 
first visit includes recording of maternal demographic characteristics and obstetric, 
medical and drug history, measurement of maternal weight and height, recording of BP 
by validated automated devices and in accordance to the recommendations of the 
American Heart Association,13, 14 and assessment of renal and liver function, including 
measurement of 24 hour urine protein and serum creatinine and aspartate 
transaminase concentration. The frequency of subsequent visits depends on BP control 
and at a minimum are carried out at 11-13 and 20-24 weeks’ gestation and four weekly 
thereafter until delivery. These visits include measurement of BP, assessment of renal 
and liver function, urinalysis for proteinuria and ultrasound examination for fetal 
anatomy and growth. In the management of patients with chronic hypertension our 
policy is to maintain the BP at 130-140 / 80-90 mmHg throughout pregnancy with use of 
antihypertensive medication. Antihypertensive drugs are stopped or their dose is 
reduced if the BP is below 130/80 mmHg in two consecutive visits. 
 
The inclusion criteria for this study were singleton pregnancies with pre-pregnancy 
chronic hypertension in the absence of renal or liver disease, presenting to the 
Antenatal Hypertension Clinic at <14 weeks’ gestation and resulting in the live birth or 
stillbirth of non-malformed babies at >24 weeks’ gestation. We excluded pregnancies 
with fetal aneuploidies or major anomalies diagnosed either prenatally or in the neonatal 
period, and pregnancies ending in miscarriage. All data were collected by two trained 
research doctors under the supervision of a senior specialist in Maternal-Fetal Medicine.    
 
The study is part of our routine clinical management and the local Research and 
Development Committee (King’s College Hospital NHS Foundation Trust) and Research 
Ethics Committee (London-Dulwich, NRES Committee) advised that formal 
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consideration was not required. Data on pregnancy outcomes were collected from the 
hospital maternity records and the women’s general medical practitioners. 
 
Outcome measures 
 
Women with pre-pregnancy chronic hypertension were stratified into three groups 
according to their BP control at the first visit to the Antenatal Hypertension Clinic. In 
group 1, the BP was <140/90 mmHg without antihypertensive medication, in group 2, 
the BP was BP <140/90 mmHg with antihypertensive medication and in group 3, the BP 
was > 140/90 despite antihypertensive medication. 
 
The outcome measures were severe hypertension, PE and birth of SGA neonates. 
Severe hypertension was defined by the presence of systolic BP >160 mmHg and / or 
diastolic BP >110 mmHg. Superimposed PE was defined according to the ISSHP-2014 
guidelines by having in addition to hypertension at least one of the following: renal 
involvement (proteinuria ≥300 mg/24h and/or creatinine ≥90 µmol/L or 1 mg/dL), liver 
impairment (transaminases >70 IU/L), neurological complications (e.g. eclampsia), 
thrombocytopenia (platelet count <150,000/µL).2 In addition, PE was subdivided 
according to gestational age at diagnosis into preterm PE with onset at <37 weeks’ 
gestation and term PE with onset at >37 weeks. Small for gestational age (SGA) was 
defined as birth weight <5th percentile for gestational age.15 As the ISSHP-2014 
guidelines recognise that the inclusion of fetal growth restriction in the definition of PE is 
controversial, we present the data on prevalence of SGA separately to those of the 
maternal features of the disease. 
 
Statistical Analysis  
 
Normality of continuous variables was assessed by the Kolmogorov-Smirnov 
test. Numerical data were expressed as mean (standard deviation) or as median 
(interquartile range) for normally and non-normally distributed data, respectively. 
Differences in maternal and pregnancy characteristics at the first hospital visit and 
pregnancy outcomes were compared between the three groups of pre-pregnancy 
chronic hypertension by the ANOVA or Kruskal-Wallis tests (for numerical parametric or 
non-parametric data) with the Bonferroni correction for post-hoc analysis. The Chi-
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square test was performed for categorical variables and the Chi-square for trend when 
the proportions between groups demonstrated an obvious trend. Multivariate logistic 
regression analysis was performed in order to assess the independent contribution of 
the three groups to pregnancy outcomes controlling for maternal demographic 
characteristics. 
 
Statistical analysis was performed using SPSS (Version 22; SPSS Inc, Chicago, IL). 
 
Results 
 
Population characteristics  
 
The study population satisfying the inclusion criteria constituted 586 women with pre-
pregnancy chronic hypertension. The median gestational age at presentation was 10.0 
(interquartile range 9.1-11.0) weeks. According to BP control at first hospital visit 199 
were classified as group 1, 220 as group 2 and 167 as group 3. During the study period 
another 104 women with pre-pregnancy chronic hypertension attended the unit but 
these were excluded from the study because 31 presented >14 weeks’ gestation, 32 
had pre-pregnancy renal or liver disease, 23 had a multiple pregnancy, 7 had major 
fetal anomalies, 37 suffered a miscarriage and 15 had incomplete data. 
 
Maternal characteristics and results of investigations at the first hospital visit in the three 
groups are compared in Table 1. Approximately 95% of patients in groups 2 and 3 were 
taking one antihypertensive drug and about 5% were taking two or more drugs. The 
most commonly used drugs were labetalol (58.4%), methyldopa (28.9%) and slow-
release nifedipine (39.3%). In groups 2 and 3, compared to group 1, there was a 
significantly higher body mass index, incidence of black racial origin and history of PE in 
a previous pregnancy; there were no significant differences between groups 2 and 3. 
There was a significant increase from group 1 to group 3 in systolic and diastolic BP 
and MAP. 
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Pregnancy outcome 
 
Pregnancy outcome measures in the three groups of women with chronic hypertension 
are compared in Table 2 and Figure 1. During the course of pregnancy, in 24.5% of 
patients in group 2 and in 6.6% in group 3 the BP remained <140/90 mmHg and the 
antihypertensive drugs were stopped. In group 1, the BP remained <140/90 mmHg 
throughout pregnancy without the need for antihypertensive medication in 62.8% of 
patients. Deterioration in BP necessitating the use of two or more antihypertensive 
medications occurred in 40.1% of women in group 3, 23.6% in group 2 and 5% in group 
1. 
 
In parallel to the use of multiple antihypertensive drugs, there was a significant increase 
from group 1 to group 3 in incidence of severe hypertension (10.6%, 22.2% and 52.1%), 
total PE (16.6%, 25.0% and 26.9%), preterm PE (7.0%, 15.9% and 20.4%), and SGA 
with birth weight <5th percentile (13.1%, 17.7% and 21.1%), but not term PE (9.5%, 
9.1% and 6.6%).  
 
In the multivariate logistic regression analysis, the risk for severe hypertension, after 
adjustment for maternal characteristics, was 9-fold higher in group 3 and 2.5-fold higher 
in group 2 compared to group 1 (Table 3). The risks of PE and SGA in groups 2 and 3 
were approximately double those of group 1.  
 
Comment 
 
Principal findings of the study  
 
The findings of this study demonstrate that in women with pre-pregnancy chronic 
hypertension presenting in the first-trimester of pregnancy there is a high incidence of 
severe hypertension (27%), PE (23%) and SGA with birthweight <5th percentile (17%). 
The study has also shown that  the incidence of severe hypertension, preterm PE and 
SGA is related to the use of antihypertensive medications and level of BP control at 
presentation in the first trimester of pregnancy; the respective incidences increased 
from 11%, 7% and 13% in those presenting with BP <140/90 mmHg without the need of 
taking antihypertensive drugs, to 22%, 16% and 18%% in those with BP <140/90 mmHg 
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after use of antihypertensive drugs, and 52%, 20% and 21% in those with BP >140/90 
mmHg despite use of antihypertensive drugs.  
 
A likely explanation for our findings is that the three subgroups of women with pre-
pregnancy chronic hypertension represent three hemodynamic profiles at different 
stages of the disease. Studies in non-pregnant individuals have demonstrated that in 
the progression from normal BP to mild and then severe hypertension there is 
increasing impairment in endothelial function which ultimately results in structural 
remodelling of small arterial resistance vessels leading to relative thickening of the 
muscular media, vasoconstriction and decreased capacity for vasodilation.16-19 In 
normal pregnancy there is early vasodilatation and decrease in peripheral resistance, 
followed by compensatory increase in blood volume and cardiac output.10 We postulate 
that pre-pregnancy chronic hypertension in group 1 represents the early phase of 
chronic hypertension with mild impairment in endothelial function and consequent ability 
to achieve the physiological adaptation to early pregnancy with normalization in BP.18, 19 
However, this group, compared to non-chronic hypertension pregnancies, is still at 
considerably higher risk for subsequent development of severe hypertension and PE. In 
group 2 there may be moderate endothelial dysfunction preventing sufficient early 
vasodilation to achieve normalization in BP; however, the condition is not so severe as 
to be non-responsive to antihypertensive drugs. Group 3 may represent severe disease 
with remodelling of small arteries and decreased capacity for response to 
antihypertensive drugs; such impairment might also predispose to subsequent 
development of PE and SGA.18, 19  
 
Preeclampsia, particularly preterm-PE, is associated with increased risk of subsequent 
maternal cardiovascular disease.20-22 In the context of chronic hypertension the 
cardiovascular disease precedes the onset of pregnancy and the link with PE may be a 
similar vascular pathology of atherosclerosis; preterm-PE is characterized by acute 
atherosis in the spiral arteries in the basal plate of the placenta.23  
 
Strengths and limitations of the study  
 
The strengths of this study are first, prospective examination of a large population of 
pregnancies with pre-pregnancy chronic hypertension presenting in the first-trimester, 
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second, exclusion of women with evidence of renal disease, because this is a risk factor 
for the development of PE independent of chronic hypertension, third, accurate 
recording of medical and drug history and use of a standardized protocol for 
measurement of BP, fourth, a standardized policy for strict control of BP throughout 
pregnancy, and fifth, stratification of patients according to the use of antihypertensive 
medications and level of BP control at the first hospital visit and reporting of rates of 
severe hypertension, PE and SGA according to such stratification.  
 
We were not able to undertake placental examination to substantiate our hypothesis 
that pre-existing endothelial dysfunction leads to placental dysfunction. Another 
limitation of the study is the lack of long-term postnatal data regarding the severity of 
chronic hypertension.  
 
Comparison with findings of other studies 
 
The association of chronic hypertension with severe hypertension, PE and SGA has 
been reported previously but not according to findings in the first-trimester.1-7 
 
In a study of 109,932 singleton pregnancies in our population attending for routine 
pregnancy care at 11-13 weeks’ gestation the overall incidence of PE was 2.3%, where 
as in the subgroup of women with pre-pregnancy chronic hypertension the incidence 
was 20.6%; after adjustment for potential confounding variables from maternal 
characteristics, medical and obstetric history, the incidence of both preterm and term PE 
in women with chronic hypertension was 5-6 times higher than in women without 
chronic hypertension.1  
 
Implications of the findings on clinical practice and future research  
 
Our study has highlighted that in women with pre-pregnancy chronic hypertension there 
is a high-risk of severe hypertension, PE and SGA despite a policy of aiming to maintain 
the BP at 130-140 / 80-90 mmHg throughout pregnancy. It is uncertain if the incidence 
of these complications would have been different if the control of BP was tighter, aiming 
to maintain the BP at <130/80 mmHg, or less tight, aiming for BP at <160/105 mmHg. 
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In non-pregnant individuals with hypertension, there is evidence that the target BP 
should be very low, because the risk of cardiovascular disease increases with 
increasing systolic BP above 115 mmHg;24 a large trial demonstrated that intensive 
treatment aiming to maintain the systolic BP at less than 120 mm Hg, as compared with 
less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major 
cardiovascular.25 In pregnancy, there is reluctance to recommend therapy in mild to 
moderate disease because reduction in BP or the drugs themselves may have an 
adverse effect on fetal growth.26, 27 Consequently, the American College of 
Obstetricians and Gynecologists (ACOG) recommends that in pregnancies of women 
with chronic hypertension treatment should be initiated only if the systolic BP is >160 
mmHg and the diastolic BP is >105 mmHg. 3, 28 However, in these meta-analyses most 
patients had gestational hypertension, rather than CH and in most studies therapy was 
initiated in the late second or early third trimester.26, 27 A trial in women with mild chronic 
hypertension at 6-13 weeks’ gestation, reported no difference in the risk of PE or SGA 
between a policy of antihypertensive treatment and one of no treatment.29 A recent trial 
of women with chronic hypertension or gestational hypertension and diastolic BP of 90-
105 mm Hg at a median gestational age of 24 (range 14-33) weeks, compared a policy 
of tight control in BP with a target diastolic BP of  85 mm Hg with a policy of less-tight 
control with target diastolic BP of 100 mm Hg; development of severe hypertension was 
lower in the tight-control group (28% vs. 41%) but there was no significant difference 
between the two policies in incidence of PE or SGA.30  
 
Alternative strategies in the management of pre-pregnancy chronic hypertension 
presenting in the first-trimester aimed at reducing the risk of PE and SGA include the 
prophylactic use of aspirin, pravastatin or metformin. In the ASPRE trial, which reported 
that aspirin (150 mg/day) from 11-14 to 36 weeks’ gestation in pregnancies at high-risk 
for PE was associated with >60% reduction in the incidence of preterm-PE, the 
beneficial effect of aspirin did not apply in pregnancies with CH.31, 32  However, there is 
some evidence that statins and metformin, which inhibit secretion of the angiogenic 
factor soluble Fms-like tyrosine kinase-1 (sFLT-1) and decrease markers of endothelial 
dysfunction and inflammation, may reduce the rate of PE.33-37  Future trials investigating 
the potential value of such medications in patients with pre-pregnancy chronic 
hypertension should stratify the population according to the approach proposed in this 
study because the effect of the drugs is likely to vary according to the severity of the 
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underlying disease.  
 
Conclusions  
 
In women with pre-pregnancy chronic hypertension there is a high risk of severe 
hypertension, PE and SGA and the incidence of these complications is related to the 
use of antihypertensive medications and level of BP control at presentation in the first 
trimester of pregnancy. 
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Figure legend 
 
Figure 1. Pregnancy complications in women with pre-pregnancy chronic hypertension  
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 1: Maternal characteristics and results of investigations at the booking visit in women with pre-pregnancy chronic 
hypertension stratified according to blood pressure control at first hospital visit. 
 
IQR = interquartile range. P-value <0.05 represents a statistically significant difference between the three subgroups in the 
Kruskal-Wallis (numerical data) or chi-square for trend (categorical data). ⃰ Statistically significant difference between group 1 
compared to groups 2 and 3, § Statistically significant difference between group 3 compared to groups 1 and 2. 
Clinical feature Total population (n=586) 
No antihypertensives Antihypertensives 
P value Normotensive 
 (Group 1, n=199) 
Normotensive 
(Group 2, n=220) 
Hypertensive 
(Group 3, n=167) 
Antihypertensive medications      
   One drug, n (%) 363 (61.9) - 207 (94.1) 156 (93.4) 0.68 
   Two or more drugs, n (%) 24 (4.1) - 13 (5.9) 11 (6.6) 0.68 
Gestational age in weeks, median (IQR) 9.0 (10.0-11.0) 10.0 (9.3-11.0) 10.0 (9.1-10.8) 10.0 (9.0-10.9) 0.108 
Age in years, median (IQR) 35.0 (31.0-38.0) 34.0 (30.0-37.5)* 35.0 (32.0-38.0) 35.0 (31.0-39.0) 0.005 
Body mass index in kg/m2, median (IQR) 31.0 (26.0-35.0) 28.0 (25.0-33.1)* 31.1 (26.0-35.0) 32.0 (28.0-37.0) <0.0001 
Weight in kg, median (IQR) 83.3 (69.7-95.9) 79.4 (67.0-91.5)* 84.0 (70.6-95.2) 87.8 (73.5-103.1) <0.0001 
Height in meters, median (IQR) 1.65 (1.6.0-1.68.) 165.0 (160.5-169.0) 165.0 (160.0-168.0) 165.0 (160.0-169.0) 0.58 
Family history of PE, n (%) 75 (12.8) 25 (12.6) 26 (11.8) 24 (14.4) 0.75 
Multiparous, n (%) 403 (68.8) 112 (56.3)* 174 (79.1) 117 (70.1) <0.0001 
Preeclampsia in previous pregnancy, n (%) 230 (39.2) 51 (25.6)* 107 (48.6) 72 (43.1) <0.0001 
Racial origin      
   Black, n (%) 359 (61.3) 99 (49.7)* 148 (67.3) 112 (67.1) <0.0001 
   Caucasian, n (%) 176 (30.0) 81 (40.7)* 51 (23.2) 44 (26.3) <0.0001 
   South-East Asian, n (%) 23 (3.9) 9 (4.5) 13 (5.9) 1 (0.6) 0.07 
   Other, n (%) 28 (4.8) 10 (5.0) 8 (3.6) 10 (6.0) 0.70 
Systolic BP in mmHg, median (IQR) 130 (120-139) 120 (112-130) 124 (120-130) 145 (140-152)§ <0.0001 
Diastolic BP in mmHg, median (IQR) 80 (74-86) 76 (70-80) 80 (72-81) 90 (84-97)§ <0.0001 
Serum creatinine in µmol/L, median (IQR) 50 (45-58) 49 (42-57) 51 (46-58) 52 (45-62) 0.005 
Aspartate transaminase in IU/L, median (IQR) 19 (16-22) 19 (16-23) 18 (16-22) 18 (16-21) 0.61 
24 hour urine protein >300 mg, n (%) 0(0) 0(0) 0(0) 0(0) - 
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Table 2: Pregnancy outcome in women with pre-pregnancy chronic hypertension stratified according to blood pressure control at 
first hospital visit. 
 
 
IQR = interquartile range. P-value <0.05 represents a statistically significant difference between the three subgroups in the 
Kruskal-Wallis (numerical data) or chi-square for trend (categorical data).  
⃰  Statistically significant difference between group 1 compared to groups 2 and 3, ¶ Statistically significant difference between group 
2 compared to group 1 § Statistically significant difference between group 3 compared to groups 1 and 2.  
 
 
 
Outcome Total population (n=586) 
No antihypertensives Antihypertensives P value 
Normotensive 
 (Group 1, n=199) 
Normotensive 
(Group 2, n=220) 
Hypertensive  
(Group 3, n=167)  
Severe hypertension, n (%) 159 (27.1) 21 (10.6) 51 (22.2) 87 (52.1) <0.0001 
   Antihypertensive medications at delivery      
   No drugs, n (%) 190 (32.4) 125 (62.8)  54 (24.5) 11 (6.6) < 0.0001 
   One drug, n (%) 267 (45.5) 64 (32.2) ⃰ 114 (51.8) 89 (53.3)  
   Two or more drugs, n (%) 129 (22.0) 10 (5.0) 52 (23.6) 67 (40.1) < 0.0001 
Preeclampsia, n (%)      
   Total, n (%) 133 (22.7) 33 (16.6) 55 (25.0) 45 (26.9) 0.01 
   Onset <37 weeks, n (%) 83 (14.2) 14 (7.0) 35 (15.9) 34 (20.4) 0.0002 
   Onset ≥ 37 weeks, n (%) 50 (8.5) 19 (9.5) 20 (9.1) 11 (6.6) 0.32 
   Gestation at onset, median (IQR) 35.6 (32.7-38.0) 37.1 (34.2-39.0) 35.7 (33.5-37.9) 34.6 (30.1-38.3) 0.09 
Small for gestational age, n (%)  100 (17.1) 26 (13.1) 39 (17.7) 35 (21.1) 0.04 
Birth weight percentile, median (IQR) 27.2 (8.3-53.3) 30.7 (11.2-56.9)  28.5 (7.3-52.2) 22.4 (7.6-48.8) 0.07 
Gestation at delivery, median (IQR) 38.8 (37.5-39.7) 39.1 (38.0-40.0)* 38.7 (37.5-39.5) 38.7 (37.0-39.5) 0.001 
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Table 3: Multivariate logistic regression analysis for adverse pregnancy outcomes in 
women with pre-pregnancy chronic hypertension stratified according to blood pressure 
control at first hospital visit. 
 
 
Adverse pregnancy outcome B value Odds Ratio 95% CI P value 
Severe hypertension     
Hypertensive despite medication (Group 3) 2.22 9.2 5.34 - 15.89 <0.0001 
Normotensive with medication  (Group 2) 0.93 2.5 1.47 – 4.43 0.001 
Normotensive without medication (Group 1)  reference   
Preeclampsia     
Hypertensive despite medication (Group 3) 0.57 1.8 1.06 – 3.13 0.03 
Normotensive with medication  (Group 2) 0.53 1.7 1.02 – 2.79 0.02 
Normotensive without medication (Group 1)  reference   
Black race  0.56 1.7 1.11 – 2.75 0.01 
Family history of preeclampsia 0.59 1.8 1.05 – 3.13 0.03 
Small for gestational age (<5th percentile)     
Hypertensive despite medication (Group 3) 0.74 2.10 1.30 – 3.38 0.002 
Normotensive with medication  (Group 2) 0.53 1.71 1.08 – 2.70 0.02 
Normotensive without medication (Group 1)  reference   
Previous preeclampsia 0.55 1.75 1.20 – 2.54 0.003 
Black race -0.45 0.64 0.43 – 0.94 0.02 
Other race  -1.03 0.35 0.13 – 0.99 0.04 
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